Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Short-term treatment of primary fibromyalgia with 5-HT3-receptor antagonist tropisetron - results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients